Rush to Develop ‘Chemically Modified Drug’ of Amosartan

Many pharmaceutical companies rush to develop chemically modified drug of antihypertension that is modeled on Hanmi Amosartan.

They have been launching forth on commercialization with the goal of a license after the PMS expiration date of Amorsartan which is March 30, 2015.

On September 11, according to the industry, 15 companies with the head of Korea United Pharm, Dream Pharma, and Huons, a...